Open-Label Safety Study of AXS-05 in Subjects With Depression
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04039022 |
Recruitment Status :
Completed
First Posted : July 31, 2019
Last Update Posted : December 17, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Major Depressive Disorder Treatment Resistant Depression Depression | Drug: AXS-05 | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 876 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Major Depressive Disorder |
Actual Study Start Date : | July 8, 2019 |
Actual Primary Completion Date : | October 23, 2020 |
Actual Study Completion Date : | October 23, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: AXS-05 (dextromethorphan and bupropion) |
Drug: AXS-05
Oral tablets, taken twice daily for up to 12 months. |
- Types and rates of adverse events [ Time Frame: Up to 12 months ]Safety
- Montgomery-Åsberg Depression Rating Scale (MADRS) [ Time Frame: Up to 12 months ]The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of major depressive disorder, including treatment resistant depression
- Body mass index (BMI) between 18 and 40 kg/m^2, inclusive
- Agree to use adequate method of contraception for the duration of the study
- Additional criteria may apply
Exclusion Criteria:
- Suicide risk
- Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
- Additional criteria may apply

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04039022

Responsible Party: | Axsome Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT04039022 |
Other Study ID Numbers: |
AXS-05-303 |
First Posted: | July 31, 2019 Key Record Dates |
Last Update Posted: | December 17, 2020 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Depression AXS-05 Dextromethorphan Bupropion Dopamine Reuptake Inhibitor NMDA Receptor Antagonist Nicotinic Acetylcholine Receptor Antagonist |
Serotonin Reuptake Inhibitor Axsome Therapeutics Norepinephrine Reuptake Inhibitor Sigma-1 Receptor Agonist Glutamate Modulator Antidepressant |
Depression Depressive Disorder Depressive Disorder, Major Depressive Disorder, Treatment-Resistant |
Behavioral Symptoms Mood Disorders Mental Disorders |